Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Sally Paterson
Trade Marks
Webinars

Celltrion Files Australian Application for Biosimilar Secukinumab

Nov 12, 2026

On 12 November 2026, Celltrion announced that it has filed an application with Australia’s Therapeutic Goods Administration for approval of Besequma® (CT-P55), biosimilar to Novartis’ Cosentyx® (secukinumab).  The application is for all approved indications of Cosentyx®.

Celltrion’s Australian application follows its submission of marketing approval applications for CT-P55 in Europe and the US (July 2026), Korea (June 2026) and Canada (May 2026).

Celltrion presented results from its Phase 1 trial for CT-P55 in September 2025.  In February 2026, Celltrion received approval from the EMA to reduce patient numbers enrolled in its global Phase 3 clinical trial for CT-P55.

On 26 October 2026, Bio-Thera announced that it received the first approval for a secukinumab biosimilar by any major regulatory agency in the world when it obtained marketing authorisation in China for BAT2306, marketed as Youzhuomei™.  BAT2306/Youzhuomei™ is approved in China for psoriasis, ankylosing spondylitis and psoriatic arthritis.

Secukinumab biosimilars are under development by at least Taizhou Mabtech Pharmaceutical (phase 1 trial of CMAB015 completed in 2023) and Livzon Pharmaceutical Group (phase 3 clinical trial of LZM012 in plaque psoriasis).  In June 2026, CSPC Pharmaceutical announced that China’s National Medical Products Administration (NMPA) had accepted a marketing authorisation application for its Secukinumab Injection.